title: Ertapenem once a day versus piperacillin-tazobactam every 6 hours for treatment of acute pelvic infections: a prospective, multicenter, randomized, double-blind study.
abstract: OBJECTIVE
  To compare ertapenem therapy with piperacillin-tazobactam therapy for the management of acute pelvic infections.
  
  
  METHODS
  In a multicenter, double-blind study, 412 women with acute pelvic infection were assigned to one of two strata, namely obstetric/postpartum infection or gynecologic/postoperative infection, and were then randomized to ertapenem, 1 g once a day, or piperacillin-tazobactam, 3.375 g every 6 hours, both administered intravenously.
  
  
  RESULTS
  In total, 163 patients in the ertapenem group and 153 patients in the piperacillin-tazobactam group were clinically evaluable. The median duration of therapy was 4.0 days in both treatment groups. The most common single pathogen was Escherichia coli. At the primary efficacy endpoint 2-4 weeks post therapy, 93.9% of patients who received ertapenem and 91.5% of those who received piperacillin-tazobactam were cured (95% confidence interval for the difference, adjusting for strata, -4% to 8.8%), indicating that cure rates for both treatment groups were equivalent. Cure rates for both treatment groups were also similar when compared by stratum and severity of infection. The frequency and severity of drug-related adverse events were generally similar in both groups.
  
  
  CONCLUSIONS
  In this study, ertapenem was as effective as piperacillin-tazobactam for the treatment of acute pelvic infection, was generally well tolerated, and had an overall safety profile similar to that of piperacillin-tazobactam.
authors.affiliation: Keck School of Medicine at USC, Los Angeles, CA, USA.
authors.forename: Subir
authors.initials: S
authors.lastname: Roy
authors.forename: Iliana
authors.initials: I
authors.lastname: Higareda
authors.forename: Edith
authors.initials: E
authors.lastname: Angel-Muller
authors.forename: Mahmoud
authors.initials: M
authors.lastname: Ismail
authors.forename: Caren
authors.initials: C
authors.lastname: Hague
authors.forename: Ben
authors.initials: B
authors.lastname: Adeyi
authors.forename: Gail L
authors.initials: GL
authors.lastname: Woods
authors.forename: Hedy
authors.initials: H
authors.lastname: Teppler
mesh_terms: D000208:Acute Disease; D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D016001:Confidence Intervals; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D000077727:Ertapenem; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007262:Infusions, Intravenous; D007769:Lactams; D008875:Middle Aged; D034161:Pelvic Infection / Q000188:drug therapy* / Q000382:microbiology; D010397:Penicillanic Acid / Q000008:administration & dosage* / Q000031:analogs & derivatives*; D010878:Piperacillin / Q000008:administration & dosage*; D011336:Probability; D011446:Prospective Studies; D018570:Risk Assessment; D012720:Severity of Illness Index; D000078142:Tazobactam; D016896:Treatment Outcome; D047090:beta-Lactams
chemical_list: D000900:Anti-Bacterial Agents; D007769:Lactams; D047090:beta-Lactams; D010397:Penicillanic Acid; D000077727:Ertapenem; D000078142:Tazobactam; D010878:Piperacillin